Bank of New York Mellon
VRNA

Bank of New York Mellon’s Verona Pharma VRNA Stock Holding History

Bank of New York Mellon’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-102,977
Closed -$9.74M – 4271
2025
Q2 		$9.74M Sell
102,977
-5,858
-5% -$434K ﹤0.01% 1920
2025
Q1 		$6.91M Buy
+108,835
New +$6.51M ﹤0.01% 2044
2024
Q2 		– Sell
-29,676
Closed -$477K – 4271
2024
Q1 		$477K Sell
29,676
-8,498
-22% -$147K ﹤0.01% 3551
2023
Q4 		$759K Buy
38,174
+11,696
+44% +$173K ﹤0.01% 3334
2023
Q3 		$432K Sell
26,478
-2,032
-7% -$39.1K ﹤0.01% 3625
2023
Q2 		$603K Sell
28,510
-4,130
-13% -$88.1K ﹤0.01% 3485
2023
Q1 		$655K Buy
32,640
+12,435
+62% +$269K ﹤0.01% 3345
2022
Q4 		$528K Sell
20,205
-4,645
-19% -$61.9K ﹤0.01% 3512
2022
Q3 		$254K Buy
+24,850
New +$209K ﹤0.01% 3914

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of New York Mellon's VRNA Position: Q3 2025 in Review

Bank of New York Mellon sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 102,977 shares — an estimated $9.74M sold.

Bank of New York Mellon first reported a position in VRNA in Q3 2022 and held it in 9 quarters. The position peaked at $9.74M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Bank of New York Mellon reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 102,977 Verona Pharma shares in Q3 2025, an estimated $9.74M.
  • Bank of New York Mellon first reported a position in Verona Pharma in Q3 2022 and held it in 9 quarters.
  • Bank of New York Mellon's Verona Pharma position peaked at $9.74M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Bank of New York Mellon's 13F filing for Q3 2025, filed 3 Nov 2025.